

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
19 May 2023 (19.05.2023)



(10) International Publication Number
WO 2023/084445 A1

(51) International Patent Classification:

A61K 51/08 (2006.01) A61K 103/00 (2006.01)

A61P 35/00 (2006.01) A61K 103/30 (2006.01)

SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:

PCT/IB2022/060840

(22) International Filing Date:

10 November 2022 (10.11.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/278,621 12 November 2021 (12.11.2021) US

(71) Applicants: **NOVARTIS AG** [CH/CH]; Lichtstrasse 35, 4056 Basel (CH). **ADVANCED ACCELERATOR APPLICATIONS** [FR/FR]; 20 Rue Diesel, 01630 Saint-Genis-Pouilly (FR).

(72) Inventors: **AIMONE, Paola Daniela**; Novartis Pharma AG, Postfach, 4002 Basel (CH). **CHICCO, Daniela**; Advanced Accelerator Applications (Italy) S.R.L., Via dell'industria Prima Traversa, 86077 Pozzilli (Isernia) (IT). **FOLITAR, Ilya**; Novartis Pharma AG, Postfach, 4002 Basel (CH). **MARIANI, Maurizio F.**; Advanced Accelerator Applications (Italy) S.R.L., Via dell'industria Prima Traversa, 86077 Pozzilli (Isernia) (IT).

(74) Common Representative: **NOVARTIS AG**; Lichtstrasse 35, 4056 Basel (CH).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI,

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))
- in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE

(54) Title: COMBINATION THERAPY FOR TREATING LUNG CANCER

(57) Abstract: The present invention relates to methods for treating small cell lung cancer (SCLC), in particular small cell lung cancer (SCLC) in a subject in need thereof wherein a therapeutically efficient amount of a radiopharmaceutical compound comprising a SSSTR binding moiety, in particular [¹⁷⁷Lu]Lu-DOTATE is administered to said subject in combination with one or more chemotherapeutic agents, such as carboplatin and etoposide, and, optionally an immune- oncology (I/O) agent, such as tislelizumab.

WO 2023/084445 A1